Differences of Small Airways Function Between Chronic Obstructive Pulmonary Disease(COPD) and Asthma-copd Overlap(ACO)
NCT03563001 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2018-06-27
Summary
The purpose of this study is to research the differences of small airways function between subjects with diagnosis of chronic obstructive pulmonary disease(COPD) and asthma-COPD overlap(ACO).The assessment of quality of life is also carried out through questionnaires.
Conditions
- Pulmonary Disease, Chronic Obstructive
- Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
- Small Airway Disease
- Quality of Life
Interventions
- DRUG
-
Budesonide(160ug) and Formoterol(4.5ug) bid
For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
Sponsors & Collaborators
-
Zhujiang Hospital
lead OTHER
Principal Investigators
-
Huapeng Yu · Southern Medical University, China
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-06-20
- Primary Completion
- 2018-09-30
- Completion
- 2018-09-30
Countries
- China
Study Locations
More Related Trials
-
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
NCT01769898 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01908140 ·Status: COMPLETED ·Phase: PHASE3
-
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
NCT01794780 ·Status: COMPLETED ·Phase: PHASE4
-
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01047553 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
NCT03022097 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT03276078 ·Status: COMPLETED ·Phase: PHASE2
-
Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD
NCT02296047 ·Status: COMPLETED ·Phase: NA
-
Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients
NCT01796730 ·Status: COMPLETED ·Phase: PHASE4
-
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00691405 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00421122 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00929708 ·Status: COMPLETED ·Phase: PHASE2
-
Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease
NCT00268177 ·Status: COMPLETED ·Phase: PHASE3
-
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
NCT02986321 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
NCT00791518 ·Status: COMPLETED
-
Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)
NCT01332409 ·Status: COMPLETED
-
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
NCT00774761 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00690482 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
NCT04655170 ·Status: UNKNOWN ·Phase: PHASE4
-
Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?
NCT01010178 ·Status: COMPLETED ·Phase: PHASE4
-
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 ·Status: COMPLETED ·Phase: PHASE2
-
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
NCT02579850 ·Status: COMPLETED ·Phase: PHASE3
-
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
NCT05219630 ·Status: COMPLETED